Joinn Laboratories (China) Co (HKSE:06127) Interest Expense : HK$0 Mil (TTM As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Joinn Laboratories (China) Co Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Joinn Laboratories (China) Co's interest expense for the three months ended in Mar. 2025 was HK$ -1 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2025 was HK$0 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Joinn Laboratories (China) Co's Operating Income for the three months ended in Mar. 2025 was HK$ -16 Mil. Joinn Laboratories (China) Co's Interest Expense for the three months ended in Mar. 2025 was HK$ -1 Mil. Joinn Laboratories (China) Co did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Joinn Laboratories (China) Co Interest Expense Historical Data

The historical data trend for Joinn Laboratories (China) Co's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Joinn Laboratories (China) Co Interest Expense Chart

Joinn Laboratories (China) Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

-0.99

-0.52

-0.39

-3.34

-0.35

Joinn Laboratories (China) Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Interest Expense	Get a 7-Day Free Trial															-0.71	0.70	-2.01	1.95	-0.56

Joinn Laboratories (China) Co Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$0 Mil.

Joinn Laboratories (China) Co (HKSE:06127) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Joinn Laboratories (China) Co's Interest Expense for the three months ended in Mar. 2025 was HK$-1 Mil. Its Operating Income for the three months ended in Mar. 2025 was HK$-16 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2025 was HK$23 Mil.

Joinn Laboratories (China) Co's Interest Coverage for the quarter that ended in Mar. 2025 is calculated as

Joinn Laboratories (China) Co did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Joinn Laboratories (China) Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Joinn Laboratories (China) Co Ltd (HKSE:06127) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

603127:China

Address

A5 Rongjing East Street, Beijing Economic-Technological Development Area, Beijing, CHN, 100176

Website

https://www.joinnlabs.com

Joinn Laboratories (China) Co Ltd is a non-clinical contract research organization(CRO) focused on drug safety assessment. It operates in three segments: Non-clinical studies services include drug safety assessment, drug metabolism & pharmacokinetics (DMPK) studies, & pharmacology & efficacy studies; Clinical trial & related services segment provides early-stage services such as clinical CRO services, co-managed phase I clinical research units, & bioanalytical services, and: Sales of research models engages in the design, production, breeding, & sales of research models, currently including non-human primates and rodents. The majority is from the Non- Clinical studies services. Its geographical segments are China, the United States, and Other countries, of which the majority is from China.

Executives

Yi Fang Da Ji Jin Guan Li You Xian Gong Si	2102 Investment manager
Futu Trustee Limited	2301 Trustee
Ubs Group Ag	2201 Interest of corporation controlled by you
Aggregate Of Abrdn Plc Affiliated Investment Management Entities	2102 Investment manager
Fil Limited	2201 Interest of corporation controlled by you
Pandanus Associates Inc.	2201 Interest of corporation controlled by you
Pandanus Partners L.p.	2201 Interest of corporation controlled by you
Brown Brothers Harriman & Co.	2502 Approved lending agent
Fidelity Funds	2101 Beneficial owner
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Abrdn Asia Focus Plc	2101 Beneficial owner
Morgan Stanley	2201 Interest of corporation controlled by you
The Goldman Sachs Group, Inc.	2201 Interest of corporation controlled by you
Apg Asset Management N.v.	2101 Beneficial owner
Apg Groep N.v.	2101 Beneficial owner

Joinn Laboratories (China) Co Headlines

No Headlines